

## RESEARCH ARTICLE


# Relation between cost of drug treatment and body mass index in people with type 2 diabetes in Latin America

Jorge Federico Elgart<sup>1\*</sup>, Mariana Prestes<sup>1</sup>, Lorena Gonzalez<sup>1,2</sup>, Enzo Rucci<sup>1,3</sup>, Juan Jose Gagliardino<sup>1</sup>, for the QUALIDIAB Net study group<sup>¶</sup>

**1** CENEXA. Center of Experimental and Applied Endocrinology (UNLP-CONICET La Plata), School of Medicine, National University of La Plata, La Plata, Argentina, **2** School of Health Economics and Management of Healthcare Organizations, Faculty of Economic Sciences, National University of La Plata, La Plata, Argentina, **3** III-LIDI, Faculty of Informatics, National University of La Plata, La Plata, Argentina

<sup>¶</sup> Membership of the QUALIDIAB Net Study group can be found in the Acknowledgments section.

\* [jelgart@cenexa.org](mailto:jelgart@cenexa.org)

 OPEN ACCESS

**Citation:** Elgart JF, Prestes M, Gonzalez L, Rucci E, Gagliardino JJ, for the QUALIDIAB Net study group (2017) Relation between cost of drug treatment and body mass index in people with type 2 diabetes in Latin America. PLoS ONE 12(12): e0189755. <https://doi.org/10.1371/journal.pone.0189755>

**Editor:** David Meyre, McMaster University, CANADA

**Received:** July 7, 2017

**Accepted:** December 3, 2017

**Published:** December 20, 2017

**Copyright:** © 2017 Elgart et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Data Availability Statement:** All relevant data are within the paper.

**Funding:** This work was supported by the Consejo Nacional de Investigaciones Cientificas y Técnicas (CONICET) and an unrestricted grant from AstraZeneca. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** This work was supported by the Consejo Nacional de Investigaciones Cientificas

## Abstract

### Aims

Despite the frequent association of obesity with type 2 diabetes (T2D), the effect of the former on the cost of drug treatment of the latest has not been specifically addressed. We studied the association of overweight/obesity on the cost of drug treatment of hyperglycemia, hypertension and dyslipidemia in a population with T2D.

### Methods

This observational study utilized data from the QUALIDIAB database on 3,099 T2D patients seen in Diabetes Centers in Argentina, Chile, Colombia, Peru, and Venezuela. Data were grouped according to body mass index (BMI) as Normal ( $18.5 \leq \text{BMI} < 25$ ), Overweight ( $25 \leq \text{BMI} < 30$ ), and Obese ( $\text{BMI} \geq 30$ ). Thereafter, we assessed clinical and metabolic data and cost of drug treatment in each category. Statistical analyses included group comparisons for continuous variables (parametric or non-parametric tests), Chi-square tests for differences between proportions, and multivariable regression analysis to assess the association between BMI and monthly cost of drug treatment.

### Results

Although all groups showed comparable degree of glycometabolic control (FBG, HbA1c), we found significant differences in other metabolic control indicators. Total cost of drug treatment of hyperglycemia and associated cardiovascular risk factors (CVRF) increased significantly ( $p < 0.001$ ) with increment of BMI. Hyperglycemia treatment cost showed a significant increase concordant with BMI whereas hypertension and dyslipidemia did not. Despite different values and percentages of increase, this growing cost profile was reproduced in every participating country. BMI significantly and independently affected hyperglycemia treatment cost.

y Técnicas (CONICET) and an unrestricted grant from AstraZeneca. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.

## Conclusions

Our study shows for the first time that BMI significantly increases total expenditure on drugs for T2D and its associated CVRF treatment in Latin America.

## Introduction

Obesity represents a large and growing global health problem [1] significantly associated with increased morbidity and mortality [2–5], decreased quality of life [6], and increased healthcare costs [7].

Body fat distribution, particularly excess of visceral adipose tissue (VAT), usually called abdominal obesity (AO), has been associated with greater health risk [8] such as development of type 2 diabetes (T2D), cardiovascular disease (CVD), and serious hospitalization events [9–11].

The Prospective Obesity Cohort of Economic Evaluation and Determinants (PROCEED) study, a multinational observational-prospective internet-based cohort study comparing healthcare utilization of overweight/obese people with and without AO, concluded that more obese people had an increasing gradient of medical conditions, metabolic risk factors, and healthcare utilization [12]. Similar changes were reported by Dilla et al following for a 12-month period 738 patients with a mean age of 66 years and BMI of 30.6 kg/m<sup>2</sup>: each unit gain in BMI was associated with a 20.0% increase in costs for BMI gainers while loss of one unit decreased these costs by 8.0% in non-BMI gainers [13]. Milder et al. also reported that obese persons used more prescription drugs of several types, particularly cardiovascular drugs (OR 3.83 in men and 2.80 in women) and diabetes drugs (OR 5.72 in men and 3.92 in women) than normal weight persons [14]. Future healthcare costs were also higher for overweight persons, especially for those with BMIs  $\geq 30$  kg/m<sup>2</sup> [15].

Higher costs of medical treatment associated with obesity have also been observed at primary care level: the Counterweight Project Team reported that total prescribing volume was significantly higher for the group with obesity and increased two- to four fold in the case of drugs such as lipid regulators,  $\beta$ -adrenoreceptor drugs, drugs affecting the renin angiotensin system, calcium channel blockers, sulphonylureas, biguanides and other drugs as well. This increase was due to both the greater number of patients treated and the use of higher drug doses [16,17].

Despite this large and concordant information, Cawley et al suggest that although information on the effect of weight and weight loss on medical expenditures is critical for decision makers to analyze cost-effectiveness of strategies for prevention and treatment of obesity, medical care costs at specific levels of BMI are not well described [18]. Four major problems challenge this assessment: 1) different conditions affect people with and without obesity, and therefore the correlation of medical expenditure with BMI depends not only on the effect of BMI itself but also on the association of other unobserved characteristics; 2) errors in weight and height data due to frequency of self-reporting rather than direct measurements [19,20]; 3) casual association of independent and dependent variables; 4) medical expenditures are a non-linear function of BMI, and therefore, accurately estimating medical expenditures at various levels of BMI requires a nonlinear model. They concluded that savings from a given percent of reduction in BMI depends on its initial value: the saving is greater the heavier the obese individual is, and is even greater for those with diabetes. Thus, despite the frequent simultaneous

presence of T2D and obesity, the specific effect of the latest on the cost of drug treatment of this disease has not been addressed.

To provide an answer to this last issue, we now evaluated the association of overweight/obesity and BMI on the cost of drugs used for treatment of hyperglycemia and associated cardiovascular risk factors (hypertension, dyslipidemia) in people with T2D.

## Research design and methods

### Study population and sampling

This Latin American observational study utilized data from the QUALIDIAB database which includes patients seen at public and private Diabetes Service Centers in Argentina, Chile, Colombia, Peru, and Venezuela. QUALIDIAB is a program that evaluates the quality of care provided to people with diabetes in Latin America. Development of the QUALIDIAB net was based on the benefits of a common data registry in different countries to enable comparison of data to correct mistakes and strengthen successful strategies. The QUALIDIAB database includes clinical, metabolic and therapeutic indicators, information on micro and macrovascular complications, the rate of use of diagnostic and therapeutic elements and annual patient hospitalization [20–22]. All this information is reported directly by physicians during personal interviews; thereafter, data are loaded and stored in anonymous format for subsequent analysis.

We included all patients having filled out a QUALIDIAB form between January 2011 and June 2014. Therefore, records of 4124 patients with T2DM were analyzed. Their country of origin was Argentina (2246), Chile (200) Colombia (654), Peru (651), and Venezuela (373). 1025 records were excluded because we were unable to calculate BMI (due to missing data on weight, height or both); consequently, the final number of people used for the statistical analysis was 3,099.

### Data analysis

BMI was calculated for each participant: weight in kilograms/ (height in meters)<sup>2</sup>. Final BMI data were classified and divided according to the WHO definition into three groups: *Normal weight* ( $18.5 \leq \text{BMI} < 25$ ), *Overweight* ( $25 \leq \text{BMI} < 30$ ) and *Obese* ( $\text{BMI} \geq 30$ ) [1]. Within each category, we utilized clinical and metabolic indicators, as well as type of drug treatment (drug and daily dose prescribed). Drug treatment was classified by drug prescription into three groups (*Hyperglycemia*, *Hypertension* and *Dyslipidemia*).

### Cost of drug treatment calculation

Monthly expenditure on drugs was estimated by micro-costing. For that purpose, we calculated a mean unit retail price per milligram of each drug or per insulin units in each country (except Venezuela). Drug costs were obtained from representative databases in Argentina ([Alfabeta.net](http://Alfabeta.net)), Colombia (SISMED), Chile (Kairos@) and Peru (Observatorio de Precios—DIGEMID); and then converted to US dollars (\$) according to the exchange rate in August 2014 in each participating country. With these data, we estimated an average price for each drug. Monthly drug treatment expenditures was calculated individually for each patient according to resource utilization, as follows: the daily dose was multiplied by 30 (a month), then multiplied by the average price, resulting in monthly expenditures. Since the average price of each drug used was the same for different settings and countries, drug treatment cost reflects only the extent of drug utilization.

## Statistical analysis

Statistical analyses utilized the Statistical Package for Social Sciences version 15 (SPSS Inc, Chicago, IL, US). Descriptive statistics are presented as percentages and mean  $\pm$  standard deviation (SD). Group comparisons for continuous variables utilized parametric or nonparametric tests according to the data distribution profile. The Chi-square test was used to estimate differences between proportions. Multivariable regression analysis was used to evaluate the association between cost of drug treatment and BMI. For regression analysis, to account for the skewed distribution of cost of drug treatment we developed a generalized linear model (GLM) with log-link function to estimate the association between drug treatment cost and BMI, patient demographic characteristics, diabetes treatments, complications and comorbidities. When several independent variables were highly correlated with each other (correlation coefficient  $\geq 0.25$ ), only 1 variable was included in the model. For example, age and diabetes duration are highly correlated, so age was deleted from the models. While we did not consider interaction effects for our analyses, the level of significance was established as  $p \leq 0.05$ .

## Ethical statement

The study protocol was analyzed and approved by the Bioethical Committee of the National University of La Plata. This study was developed according to Good Practice Recommendations (International Harmonisation Conference) and the ethical guidelines of the Helsinki Declaration. Informed consent was waived because this retrospective study involves secondary analysis of existing database which was de-identified and anonymously stored to protect private information. Therefore, this procedure ensured compliance with the National Law 25.326 of Personal Data Protection.

## Results

Clinical and metabolic characteristics of the study population classified according to its BMI showed that only 16% of participants had BMI within the normal range, 38% were overweight, and the remaining 46% were obese (Table 1). The percentage of men was significantly greater in the overweight group than in the other two groups. Mean age was comparable in the normal and overweight groups but was significantly lower (younger) in the obese group. Duration of diabetes was lower in obese than overweight group, while was comparable in the normal and overweight groups. Although systolic and diastolic blood pressure values were within normal range in all groups, they were significantly lower in the normal weight compared to the obese group.

Fasting blood glucose (FBG) and hemoglobin A1c (HbA1c) showed comparable values in all groups; however, they were all above those recommended by the American Diabetes Association and European Association for the Study of Diabetes (ADA/EASD) guideline [23]. i.e. all studied population had a comparable degree of abnormal glycometabolic control.

Triglyceride values were above those recommended by international guidelines in the overweight and obese group, being significantly higher in the latter.

Significant differences between groups were found in hyperglycemia treatment (Table 2). The proportion of patients treated with only diet and physical activity as well as those on oral monotherapy decreased significantly in overweight/obese people, whereas administration of combined oral therapy alone or associated with insulin was significantly higher in the overweight and obese groups. No significant differences among groups were recorded in people treated only with insulin.

Total monthly *per capita* costs of drug treatment of hyperglycemia and associated cardiovascular risk factors increased significantly with BMI category ( $p < 0.001$ , Table 3). While drug

**Table 1. Characteristics of the study population.**

Parameter	All		Normal weight (18.5 ≤ BMI < 25)		Overweight (25 ≤ BMI < 30)		Obesity (BMI ≥ 30)	
	Value	n	Value	n	Value	n	Value	n
Men (%)	42.3	3099	40.0	495	47.1 *	1185	39.1 †	1419
Age (years)	62.1 ± 11.8	3079	63.9 ± 12.4	489	63.3 ± 11.7	1179	60.4 ± 11.4*†	1411
Diabetes Duration (years)	10.8 ± 9.0	2391	11.0 ± 9.7	387	11.5 ± 9.4	896	10.1 ± 8.4 †	1108
BMI (kg/m <sup>2</sup> )	30.1 ± 5.8	3099	23.0 ± 1.4	495	27.4 ± 1.4*	1185	34.9 ± 4.9*†	1419
SBP (mmHg)	129.9 ± 17.5	3053	124.8 ± 18.1	486	129.8 ± 17.5 *	1170	131.7 ± 16.9*†	1397
DBP (mmHg)	77.3 ± 10.9	3049	73.1 ± 10.9	486	76.5 ± 10.3 *	1168	79.3 ± 10.9 *†	1395
FBG (mg/dL)	152.3 ± 84.0	2842	158.2 ± 115.3	441	148.7 ± 76.6	1073	153.3 ± 77.1	1327
HbA1c (%)	7.7 ± 1.9	2739	7.7 ± 2.3	440	7.7 ± 1.8	1032	7.7 ± 1.8	1267
[mmol/mol]	[61 ± 20.8]		[61 ± 25.1]		[61 ± 19.7]		[61 ± 19.7]	
HbA1c ≤7% (%)	43.9	2739	48.2	440	43.1	1032	43.0	1267
Total Cholesterol (mg/dL)	185.6 ± 45.9	2749	181.2 ± 45.2	422	185.6 ± 44.7	1050	187.2 ± 46.9	1277
HDL-c (mg/dL)	47.4 ± 21.1	2509	51.3 ± 29.1	393	46.9 ± 14.7 *	946	46.6 ± 22.2 *	1170
LDL-c (mg/dL)	106.7 ± 35.9	2413	104.6 ± 38.4	373	107.3 ± 35.6	918	106.9 ± 35.5	1122
Triglyceride (mg/dL)	171.6 ± 108.4	2671	143.5 ± 87.8	412	162.0 ± 100.2 *	1002	188.4 ± 117.7 *†	1257
Complications (%)	56.1%	2539	59.5%	395	56.3%	969	54.8%	1175
Hypertention (%)	65.3%	2024	53.7%	266	63.3% *	750	71.0% *†	1008
Dyslipemia (%)	62.6%	1939	60.4%	299	59.4%	704	66.0% †	936

Each value represents mean ± SD (standard deviation); BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; FBG: fasting blood glucose.

\*Significant compared with normal weight (P < 0.05)

† Significant compared to overweight (p < 0.05).

<https://doi.org/10.1371/journal.pone.0189755.t001>

treatment of hyperglycemia alone showed a similar increase trend and percentage, no significant differences were observed in hypertension and dyslipidemia drug therapy.

Even with a comparable degree of glycometabolic control, overweight and obese people increased their monthly *per capita* cost of hyperglycemia medications by 14 and 38%, respectively (Table 3). Each year, overweight and obese people spent, respectively, US\$172.80 and US\$448.80 more than normal weight patients.

Since the study includes different numbers of participants from each country, we tested whether BMI and total drug treatment cost showed similar relationship or merely reflected results in a particular country with a larger representation. Although the values differed and the percentage of increase varied, the growing cost profile was reproduced in every participating country (Fig 1). In this regard, the largest and lowest increases were recorded in Venezuela and Colombia, respectively. Since the average price of each drug utilized was the same in the different countries, these differences might be probably ascribed, at least partly, to the quantity of drug utilization.

Multivariable regression analysis showed that total expenditure of drugs was significant and independently associated with gender, BMI, systolic blood pressure (SBP) and LDL-cholesterol, levels, hypertension, dyslipidemia and treatment of T2D (Table 4). Total expenditure on drugs was 7.3% higher in male than in female while total drugs treatment costs were higher in patients with hypertension or dyslipidemia (1.417 and 2.077, respectively). Further, each point of change in BMI was associated with a 1.3% increase in the total drugs expenditure. The analysis also showed that expenditure for hyperglycemia drugs treatment was significantly

**Table 2. Type of hyperglycemia medications treatment by BMI categories.**

Treatment	All		Normal weight (18.5 ≤ BMI < 25)		Overweight (25 ≤ BMI < 30)		Obesity (BMI ≥ 30)	
	%	n	%	n	%	n	%	n
<b>Only diet and Phys. activity</b>	<b>2.9</b>	<b>91</b>	<b>5.2</b>	<b>26</b>	<b>3.2*</b>	<b>38</b>	<b>1.9*†</b>	<b>27</b>
<b>OAD Monotherapy</b>	<b>29.9</b>	<b>928</b>	<b>35.4</b>	<b>175</b>	<b>29.0*</b>	<b>344</b>	<b>28.8*</b>	<b>409</b>
<i>Metformin</i>	84.5	770	75.0	132	82.8*	284	90.3*†	354
<i>SU</i>	10.3	94	14.8	26	12.2	42	6.6*†	26
<i>DPP-4</i>	4.5	41	10.2	18	4.1*	14	2.3*	9
<i>Other (%)</i>	0.7	6	0.0	0	0.9	3	0.8	3
<b>Combined OAD (2 or more)</b>	<b>29.0</b>	<b>898</b>	<b>24.8</b>	<b>123</b>	<b>29.5</b>	<b>350</b>	<b>30.0</b>	<b>425</b>
<i>Metformin (%)</i>	97.6	898	96.0	119	97.7	344	98.0	435
<i>SU (%)</i>	74.9	689	73.4	91	75.9	267	74.5	331
<i>DPP-4 (%)</i>	32.0%	294	35.5	44	32.4	114	30.6	136
<i>Other (%)</i>	8.2	75	1.6	2	4.5	16	12.8*†	57
<b>Insulin + OAD (1 or more)</b>	<b>23.1</b>	<b>715</b>	<b>17.6</b>	<b>87</b>	<b>22.3 *</b>	<b>264</b>	<b>25.6 *†</b>	<b>364</b>
<b>Insulin alone</b>	<b>15.1</b>	<b>467</b>	<b>17.0</b>	<b>84</b>	<b>16.0</b>	<b>189</b>	<b>13.7</b>	<b>194</b>

OAD: Oral antidiabetic drugs; SU: sulfonylureas; DPP-4: dipeptidil peptidasa-4.

\*Significant compared with normal weight (P < 0.05)

† Significant compared to overweight (p < 0.05).

<https://doi.org/10.1371/journal.pone.0189755.t002>

associated with gender, duration of diabetes, BMI and LDL-cholesterol values, dyslipidemia, T2D complications and type of drugs employed.

## Discussion

Our data show that increase in BMI is associated with a parallel growth in overall drugs treatment cost of hyperglycemia and its associated cardiovascular risk factors. This effect was observed despite comparable values for FBG/HbA1c and blood pressure found in each BMI classified group. However, impaired serum lipid profile, characterized by significantly high tri-glyceride level, was recorded mainly in the overweight/obese groups. Based on these results and the fact that treatment costs were expressed *per capita*, we could assume that people with higher BMI required larger quantities of drugs to attain a given blood glucose treatment target.

**Table 3. Monthly cost of drug treatment per capita by risk factor and BMI categories.**

Treatment	Normal weight (18.5 ≤ BMI < 25)		Overweight (25 ≤ BMI < 30)			Obesity (BMI ≥ 30)			p value (between groups) <sup>b</sup>
	Mean ± SD	n	Mean ± SD	Ratio <sup>a</sup>	n	Mean ± SD	Ratio <sup>a</sup>	n	
Hyperglycemia	\$61.0 ± 55.4	469	\$69.6 ± 57.7 *	1.14	1147	\$84.5 ± 76.3 *†	1.38	1392	<0.001
Hypertension	\$40.1 ± 30.1	232	\$42.7 ± 33.3	1.06	666	\$44.4 ± 37.6	1.11	908	0.289
Dyslipidemia	\$73.1 ± 36.8	234	\$74.2 ± 41.8	1.02	534	\$70.0 ± 39.5	0.96	702	0.088
Total cost (All together)	\$113.8 ± 83.8	495	\$128.2 ± 89.3 *	1,13	1185	\$151.2 ± 109.4 *†	1.33	1419	<0.001

Costs of treatment are expressed in US dollars (\$).

<sup>a</sup>Based on Normal weight.


<sup>b</sup> Kruskal-Wallis test.

\*Significant compared with Normal weight (p < 0.05; Mann-Whitney U test)

† Significant compared to Overweight (p < 0.05; Mann-Whitney U test).

<https://doi.org/10.1371/journal.pone.0189755.t003>





**Fig 1. Total cost of drug treatment by country.** NW: Normal weight ( $18.5 \leq \text{BMI} < 25$ ); OW: Overweight ( $25 \leq \text{BMI} < 30$ ); O: Obesity ( $\text{BMI} \geq 30$ ).

<https://doi.org/10.1371/journal.pone.0189755.g001>

This larger drug demand could be due to the negative impact of overweight/obesity on tissue-insulin sensitivity [24].

Other authors have reported an incremental impact of overweight/obesity on health care costs for people with diabetes. Yu et al found that in patients with diabetes who gained a minimum of one pound between two weight measurements, the average 1-year total diabetes-related health care cost following the second weight measure was significantly higher than the corresponding measure for those who did not gain weight (\$2,141 vs. \$1,869, respectively;  $p = 0.006$ ). When weight gain and no gain were modeled separately, 1% weight loss was associated with a 5.8% (\$131;  $p < 0.01$ ) decrease in diabetes-related cost; the economic benefit of weight loss was higher in the group with  $\text{BMI} \geq 30 \text{ kg/m}^2$  [25]. Similarly, Apovian et al reported that obesity is associated with a more than 13-fold increase in expenditure on antidiabetic medications [26].

Despite differences in the magnitude of the cost increase, similar trends were reported regarding the association of BMI on general drug consumption at every level of care complexity [16,17,27,28] and in different health care settings [29–31]. Further, both old and new reports [3,15] as well as current studies of care costs have shown the same trend [7,15].

Although with different values, we found similar association between BMI and medication costs in each participating country (Fig 1). Since we cannot assure that overweight/obesity

Table 4. Multivariable regression analysis.

Explanatory Variable	Model 1					Model 2				
	Total cost of drug treatment					Cost of hyperglycemia drug treatment only				
	Original regression coefficient	p value	Exponential <sup>a</sup>	95% CI		Original regression coefficient	p value	Exponential <sup>a</sup>	95% CI	
				Lower	Upper				Lower	Upper
Intercept	3.310	0.000	27.397	19.959	37.607	3.333	0.000	28.012	18.916	41.481
Gender (male)	0.070	0.030	1.073	1.007	1.143	0.095	0.017	1.100	1.017	1.189
Diabetes Duration (years)	0.003	0.161	1.003	0.999	1.007	0.013	0.000	1.013	1.008	1.018
HbA1c (%)	0.016	0.099	1.017	0.997	1.036	0.020	0.101	1.020	0.996	1.044
BMI (kg/m <sup>2</sup> )	0.012	0.000	1.012	1.006	1.018	0.022	0.000	1.022	1.015	1.029
SBP (mmHg)	0.002	0.019	1.002	1.000	1.004	-0.001	0.379	0.999	0.997	1.001
LDL- Cholesterol (mg/dL)	-0.001	0.016	0.999	0.998	1.000	-0.002	0.000	0.998	0.997	0.999
Triglyceride (mg/dL)	0.000	0.194	1.000	1.000	1.001	0.000	0.978	1.000	1.000	1.000
<b>Hypertension</b>										
No (Reference)	0.000		1.000					1.000		
Yes	0.349	0.000	1.417	1.318	1.525	0.001	0.987	1.001	0.915	1.094
<b>Dyslipidemia</b>										
No (Reference)	0.000		1.000					1.000		
Yes	0.731	0.000	2.077	1.938	2.225	0.224	0.000	1.251	1.149	1.362
<b>T2D Complications</b>										
None (reference)	0.000		1.000					1.000		
Micro or Macrovascular	-0.035	0.301	0.966	0.903	1.032	-0.160	0.000	0.852	0.785	0.925
<b>Treatment of T2D</b>										
Not using insulin (reference)	0.000		1.000					1.000		
Using Insulin	0.338	0.000	1.402	1.307	1.505	0.573	0.000	1.774	1.628	1.933

<sup>a</sup> Exp (original regression coefficient).

95% CI: 95% Confidence Interval. BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure.

<https://doi.org/10.1371/journal.pone.0189755.t004>

frequency was exactly the same in all of them, this potential difference could be one of the causes for the different cost increase among countries. However, the persistence of a significant difference in every country -large despite different values- plays in favor of the strength of this phenomenon.

Higher BMI is also associated with higher indirect costs and lower productivity, consequently, its negative impact affects not only health care costs but also many other social factors [27,32,33].

Despite the known negative effects of overweight/obesity associated with T2D on health care costs, productivity, and society, plus the availability of effective strategies for its prevention and treatment [34,35], both obesity and T2D show progressive growth worldwide, reaching epidemic levels [36].

Behavioral treatment of obesity at the primary care level including monthly counseling visits and a choice of meal replacements or weight loss medication could be a cost-effective strategy for obesity over the long term ( $\geq 10$  years) [37]. More aggressive strategies such as bariatric surgery, when appropriately prescribed, may lead to significant cost savings for health care systems [38]. In fact, people with T2D who undergo bariatric surgery may also decrease drug treatment costs compared to those in conventional treatment (\$14,346 vs. \$19,511;



$p < 0.0001$ ) [39]. Further, NICE guideline recommends bariatric surgery as a clinically- and cost-effective option for obese patients with T2D, particularly those with severe obesity [40]. Altogether, all these data suggests that implementation of a large scale weight loss program could effectively decrease this multisectorial disease burden.

If we consider that overweight and obesity: a) increased the monthly *per capita* cost of hyperglycemia drug treatment by 14 and 38%, respectively; b) result in an annual expenditure of \$172.80 and \$448.80, respectively, higher than for T2D patients with normal weight in order to reach comparable degrees of glycometabolic control and c) overweight/obese people represent 84% of the Latin American T2D population, these three conditions clearly impose a heavy burden on the health care budget. Therefore, this situation should alert health policy makers on the importance of implement effective strategies to reduce overweight and obesity in people with T2D.

Although clear and significant, our results should be considered with caution due to several limitations such as a) it is an observational rather than a prospective study; b) the population studied was not entirely representative of a population base; c) its total number of cases is strongly influenced by one participating country (Argentina) and d) we have not considered neither the physical activity load nor adherence to healthy meal plan thus, we do not know whether such conditions could affect all the BMI conditions in a comparable manner; e) data were reported by specialized diabetes facilities. However, we have shown that the cost profile was comparable in every participating country, and other authors have also shown that in different countries the impact of BMI on drug-treatment costs occurs even at the primary care level [16,17]. In this context, our results seem to reflect a general process rather than local or other bias.

## Conclusions

In brief, our study shows a significant association between BMI and the total cost of drug treatment for T2D and its associated cardiovascular risk factors in Latin America. They also suggest that implementation of effective obesity preventive strategies might significantly decrease the burden of T2D on healthcare costs and other social factors.

## Acknowledgments

The authors thank the participants in QUALIDIAB Net as well as the staff at all the investigator sites. The authors also thank William H. Herman for his useful comments and suggestions. LG is a doctoral fellow of the Universidad Nacional de La Plata (UNLP), MP is a doctoral fellow of the Comisión de Investigaciones Científicas de la Provincia de Buenos Aires (CIC-PBA) and UNLP; ER is a postdoctoral fellow of the Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), while JFE and JJG are members of the Research Career of CONICET. The following people are members of the QUALIDIAB Net Study Group (listed in alphabetical order): Pablo Aschner (Pontificia Universidad Javeriana, Hospital Universitario San Ignacio, Bogotá, Colombia), Alejandra Cicchitti (Hospital Universitario, Universidad Nacional de Cuyo, Mendoza, Argentina), Victor Commendatore (Servicio de Endocrinología, Diabetes y Nutrición, Hospital San Martín, Entre Ríos, Argentina), Silvia De Carolis (Salta, Argentina), Rocío Delgado (Clínica Integral de Diabetes, Medellín, Colombia), Cristina Du Plessis (San Miguel de Tucuman, Tucuman, Argentina), María C Faingold (Unidad Asistencial Por Más Salud "Dr. Cesar Milstein", Buenos Aires, Argentina), Graciela Fuente (Unidad de Nutrición, Hospital "Carlos G. Durand", Buenos Aires, Argentina), Joaquín Gonzalez (Hospital Universitario, Universidad Nacional de Cuyo, Mendoza, Argentina), Silvia Lapertosa (Facultad de Medicina, Universidad Nacional del Nordeste, Corrientes, Argentina), Dilcia Lujan

(Asociación Colombiana de Diabetes, Bogotá, Colombia), Helard Manrique (Servicio de Endocrinología, Hospital Nacional Arzobispo Loayza, Lima, Perú), Franco Mio Palacio (Hospital Augusto Hernandez Mendoza, Ica, Peru), Ana M Miskiewicz (Departamento de Endocrinología y Enfermedades Metabólicas, Hospital Militar Dr. Carlos Arvelo, Caracas, Venezuela), Miguel A Padrón (Fundación Antidiabética, Caracas, Venezuela), Federico Perez Manghi (Centro de Investigaciones Metabólicas, Buenos Aires, Argentina), Doris Ramirez de Peña (Facultad de Medicina, Universidad Nacional de Colombia. Bogotá, Colombia), Sergio Rueda (Hospital Dr. Guillermo Rawson, San Juan, Argentina), Carmen L Solís (Asociación de Diabéticos de Chile, Santiago, Chile), Lucas Sosa (Servicio de Endocrinología y Metabolismo, Hospital Raúl Matera, Bahía Blanca, Argentina), Victoria Stepenka (Instituto Zuliano de Diabetes, Universidad del Zulia, Hospital General del Sur, Maracaibo, Venezuela), Maria R Urdangarin (Hospital Zonal Zapala, Neuquén, Argentina), Jaime Villena Chávez (Servicio de Endocrinología, Hospital Nacional Cayetano Heredia, Lima, Perú), Edwin A Wandurruga (Universidad Autónoma de Bucaramanga—FOSCAL, Bucaramanga, Colombia).

**Prior presentation:** This work was presented as a poster at the 23rd World Diabetes Congress of the International Diabetes Federation, Vancouver, Canada, 30 November—4 December 2015.

## Author Contributions

**Conceptualization:** Jorge Federico Elgart, Juan Jose Gagliardino.

**Data curation:** Jorge Federico Elgart, Mariana Prestes, Lorena Gonzalez, Enzo Rucci.

**Formal analysis:** Jorge Federico Elgart, Mariana Prestes, Lorena Gonzalez, Juan Jose Gagliardino.

**Investigation:** Jorge Federico Elgart, Lorena Gonzalez, Juan Jose Gagliardino.

**Methodology:** Jorge Federico Elgart, Juan Jose Gagliardino.

**Project administration:** Jorge Federico Elgart.

**Resources:** Mariana Prestes, Lorena Gonzalez, Enzo Rucci.

**Software:** Enzo Rucci.

**Supervision:** Jorge Federico Elgart, Juan Jose Gagliardino.

**Validation:** Enzo Rucci.

**Writing – original draft:** Jorge Federico Elgart, Mariana Prestes, Lorena Gonzalez, Juan Jose Gagliardino.

**Writing – review & editing:** Jorge Federico Elgart, Juan Jose Gagliardino.

## References

1. World Health Organization (WHO). Obesity: preventing and managing the global epidemic (WHO). Report of a WHO Expert Committee. WHO Technical Report Service no. 894. Geneva: WHO, 2000.
2. Willett WC, Manson JE, Stampfer MJ, Colditz GA, Rosner B, Speizer FE, et al. Weight, weight change, and coronary heart disease in women. Risk within the 'normal' weight range. *JAMA* 1995; 273(6): 461–5. PMID: [7654270](https://pubmed.ncbi.nlm.nih.gov/7654270/)
3. Lehnert T, Streltchenia P, Konnopka A, Riedel-Heller SG, König HH. Health burden and costs of obesity and overweight in Germany: an update. *Eur J Health Econ* 2014; 16(9):957–67. <https://doi.org/10.1007/s10198-014-0645-x> PMID: [25381038](https://pubmed.ncbi.nlm.nih.gov/25381038/)

4. Stevens J, Cai JW, Pamuk ER, Williamson DF, Thun MJ, Wood JL. The effect of age on the association between body mass index and mortality. *N Engl J Med* 1998; 338:1–7. <https://doi.org/10.1056/NEJM199801013380101> PMID: 9414324
5. Patel AV, Hildebrand JS, Gapstur SM. Body mass index and all-cause mortality in a large prospective cohort of white and black US Adults. *PLoS One* 2014; 9(10):e109153. <https://doi.org/10.1371/journal.pone.0109153> PMID: 25295620
6. Wee CC, Davis RB, Chiodi S, Huskey KW, Hamel MB. Sex, Race, and the Adverse Effects of Social Stigma vs. Other Quality of Life Factors Among Primary Care Patients with Moderate to Severe Obesity. *J Gen Intern Med* 2015; 30(2):229–35. <https://doi.org/10.1007/s11606-014-3041-4> PMID: 25341644
7. Dee A, Kearns K, O'Neill C, Sharp L, Staines A, O'Dwyer V, et al. The direct and indirect costs of both overweight and obesity: a systematic review. *BMC Res Notes* 2014; 7:242. <https://doi.org/10.1186/1756-0500-7-242> PMID: 24739239
8. Shen W, Wang Z, Punyanita M, Shen W, Wang Z, Punyanita M, et al. Adipose tissue quantification by imaging methods: a proposed classification. *Obes Res* 2003; 11:5–16. <https://doi.org/10.1038/oby.2003.3> PMID: 12529479
9. Kekäläinen P, Sarlund H, Pyörala K, Laakso M. Hyperinsulinemia cluster predicts the development of type 2 diabetes independently of family history of diabetes. *Diabetes Care* 1999; 22(1): 86–92. PMID: 10333908
10. Isomaa B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, et al. Cardiovascular morbidity and mortality associated with metabolic syndrome. *Diabetes Care* 2001; 24(4):683–9. PMID: 11315831
11. Alexander CM, Landsman PB, Teutsch SM, Haffner SM. NCEP-defined metabolic syndrome, diabetes and prevalence of coronary heart disease among NHANES III participants age 50 years and older. *Diabetes* 2003; 52(5):1210–4. PMID: 12716754
12. Kit BK, Ogden CL, Flegal KM. Prescription Medication Use Among Normal Weight, Overweight, and Obese Adults, United States, 2005–2008. *Ann Epidemiol* 2012; 22(2):112–9. <https://doi.org/10.1016/j.annepidem.2011.10.010> PMID: 22100542
13. Dilla T, Valladares A, Nicolay C, Salvador J, Reviriego J, Costi M. Healthcare Costs Associated with Change in Body Mass Index in Patients with Type 2 Diabetes Mellitus in Spain: The ECOBIM Study. *Appl Health Econ Health Policy* 2012; 10(6):417–30. <https://doi.org/10.2165/11634030-000000000-00000> PMID: 23013427
14. Milder IEJ, Klungel OH, Mantel-Teeuwisse AK, Verschuren WM, Bemelmans WJ. Relation between body mass index, physical inactivity and use of prescription drugs: the Doetinchem Cohort Study. *International J Obesity* 2010; 34(6):1060–9. <https://doi.org/10.1038/ijo.2010.2> PMID: 20125097
15. Thompson D, Brown JB, Nichols GA, Elmer PJ, Oster G. Body mass index and future healthcare costs: a retrospective cohort study. *Obes Res* 2001; 9(3):210–8. <https://doi.org/10.1038/oby.2001.23> PMID: 11323447
16. Counterweight Project Team. The impact of obesity on drug prescribing in primary care. *British J Gen Practice* 2005; 55(519):743–9.
17. Counterweight Project Team. Influence of body mass index on prescribing costs and potential cost savings of a weight management programme in primary care. *J Health Serv Res Policy* 2008; 13(3):158–66. <https://doi.org/10.1258/jhsrp.2008.007140> PMID: 18573765
18. Cawley J, Meyerhoefer C, Biener A, Hammer M, Wintfeld N. Savings in Medical Expenditures Associated with Reductions in Body Mass Index Among US Adults with Obesity, by Diabetes Status. *Pharmacoeconomics* 2015; 33(7):707–22. <https://doi.org/10.1007/s40273-014-0230-2> PMID: 25381647
19. Finkelstein EAE, Trogdon JGJ, Cohen JJW, Dietz W. Annual medical spending attributable to obesity: payer- and service-specific estimates. *Health Aff (Millwood)*. 2009; 28(5): w822–831. <https://doi.org/10.1377/hlthaff.28.5.w822> PMID: 19635784
20. Gagliardino JJ, de la Hera M, Siri F; Grupo de Investigación de la Red QUALIDIAB. Evaluation of the quality of care for diabetic patients in Latin America. *Rev Panam Salud Publica* 2001; 10(5):309–17. PMID: 11774802
21. Commendatore V, Dieuzeide G, Faingold C, Fuente G, Luján D, Aschner P, et al. Registry of people with diabetes in three Latin American countries: a suitable approach to evaluate the quality of health care provided to people with type 2 diabetes. *Int J Clin Pract* 2013; 67(12):1261–6. <https://doi.org/10.1111/ijcp.12208> PMID: 24246207
22. Elgart JF, González L, Prestes M, Rucci E, Gagliardino JJ. Frequency of self-monitoring blood glucose and attainment of HbA1c target values. *Acta Diabetol* 2016; 53(1):57–62. <https://doi.org/10.1007/s00592-015-0745-9> PMID: 25841589

23. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al. Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care* 2015; 38(1):140–9. <https://doi.org/10.2337/dc14-2441> PMID: 25538310
24. Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. *Nature* 2006; 444(7121):840–6. <https://doi.org/10.1038/nature05482> PMID: 17167471
25. Yu AP, Wu EQ, Birnbaum HG, Emami S, Fay M, Pohl G, et al. Short-term economic impact of body weight change among patients with type 2 diabetes treated with antidiabetic agents: analysis using claims, laboratory, and medical record data. *Curr Med Res Opin* 2007; 23(9):2157–69. <https://doi.org/10.1185/0300799007X219544> PMID: 17669232
26. Apovian CM. The clinical and economic consequences of obesity. *Am J Manag Care* 2013; 19(11 Suppl):s219–28. PMID: 24669378
27. Ostbye T, Dement JM, Krause KM. Obesity and workers' compensation: results from the Duke Health and Safety Surveillance System. *Arch Intern Med* 2007; 167(8):766–73. <https://doi.org/10.1001/archinte.167.8.766> PMID: 17452538
28. Gordon B, Afek A, Livshits S, Derazne E, Tzur D, Shamiss A, et al. The association between body mass index and increased utilization of healthcare services: a retrospective cohort study of 51,521 young adult males. *Endocr Pract* 2014; 20(7):638–45. <https://doi.org/10.4158/EP13419.OR> PMID: 24449675
29. Keaver L, Webber L, Dee A, Shiely F, Marsh T, Balanda K, et al. Application of the UK foresight obesity model in Ireland: the health and economic consequences of projected obesity trends in Ireland. *PLoS One* 2013; 8(11):e79827. <https://doi.org/10.1371/journal.pone.0079827> PMID: 24236162
30. Rtveldazde K, Marsh T, Webber L, Kilpi F, Levy D, Conde W, et al. Health and economic burden of obesity in Brazil. *PLoS One*. 2013; 8(7):e68785. <https://doi.org/10.1371/journal.pone.0068785> PMID: 23874763
31. Wolf AM, Finer N, Allshouse AA, Pendergast KB, Sherrill BH, Caterson I, et al. PROCEED: Prospective Obesity Cohort of Economic Evaluation and Determinants: baseline health and healthcare utilization of the US sample. *Diabetes, Obesity and Metabolism* 2008; 10:1248–60. <https://doi.org/10.1111/j.1463-1326.2008.00895.x> PMID: 18721258
32. Van Nuys K, Globe D, Ng-Mak D, Cheung H, Sullivan J, Goldman D. The association between employee obesity and employer costs: evidence from a panel of U.S. employers. *Am J Health Promot* 2014; 28(5):277–85. <https://doi.org/10.4278/ajhp.120905-QUAN-428> PMID: 24779722
33. Trogdon JG, Finkelstein EA, Hylands T, Dellea PS, Kamal-Bahl SJ. Indirect costs of obesity: a review of the current literature. *Obes Rev* 2008; 9(5):489–500. <https://doi.org/10.1111/j.1467-789X.2008.00472.x> PMID: 18331420
34. Liao Y, Liao J, Durand CP, Dunton GF. Which type of sedentary behaviour intervention is more effective at reducing body mass index in children? A meta-analytic review. *Obes Rev* 2014; 15(3):159–68. <https://doi.org/10.1111/obr.12112> PMID: 24588966
35. Barraj LM, Murphy MM, Heshka S, Katz DL. Greater weight loss among men participating in a commercial weight loss program: a pooled analysis of 2 randomized controlled trials. *Nutr Res* 2014; 34(2):174–7. <https://doi.org/10.1016/j.nutres.2013.11.002> PMID: 24461320
36. Yatsuya H, Li Y, Hilawe EH, Ota A, Wang C, Chiang C, et al. Global Trend in Overweight and Obesity and Its Association With Cardiovascular Disease Incidence. *Circ J* 2014; 78(12):2807–18. PMID: 25391910
37. Tsai AG, Wadden TA, Volger S, Sarwer DB, Vetter M, Kumanyika S, et al. Cost-effectiveness of a primary care intervention to treat obesity. *Int J Obes (Lond)* 2013; 37(Suppl 1):S31–7. <https://doi.org/10.1038/ijo.2013.94> PMID: 23921780
38. Borisenko O, Adam D, Funch-Jensen P, Ahmed AR, Zhang R, Colpan Z, et al. Bariatric Surgery can Lead to Net Cost Savings to Health Care Systems: Results from a Comprehensive European Decision Analytic Model. *Obes Surg* 2015; 25(9):1559–68. <https://doi.org/10.1007/s11695-014-1567-5> PMID: 25639648
39. Keating C, Neovius M, Sjöholm K, Peltonen M, Narbro K, Eriksson JK, et al. Health-care costs over 15 years after bariatric surgery for patients with different baseline glucose status: results from the Swedish Obese Subjects study. *Lancet Diabetes Endocrinol* 2015; 3(11):855–65. [https://doi.org/10.1016/S2213-8587\(15\)00290-9](https://doi.org/10.1016/S2213-8587(15)00290-9) PMID: 26386667
40. Wilding J. Managing patients with type 2 diabetes and obesity. *Practitioner* 2015; 259(1778):25–8. PMID: 25726618